Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 76Carcinoma, Non-Small-Cell Lung 73Multiple Myeloma 58Prostatic Neoplasms 57Colorectal Neoplasms 45Leukemia, Myeloid, Acute 43Neoplasms 41Melanoma 35Lymphoma 35Lung Neoplasms 32Ovarian Neoplasms 31Lymphoma, Non-Hodgkin 30Squamous Cell Carcinoma of Head and Neck 29Sarcoma 28Neoplasm Metastasis 27Pancreatic Neoplasms 26Endometrial Neoplasms 25Carcinoma, Hepatocellular 25Hodgkin Disease 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Lymphoma, Large B-Cell, Diffuse 22Leukemia, Lymphocytic, Chronic, B-Cell 22Glioma 22Recurrence 21Urinary Bladder Neoplasms 20Myelodysplastic Syndromes 20Head and Neck Neoplasms 20Esophageal Neoplasms 17Stomach Neoplasms 16

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Castrate Sensitive Prostate Cancer × 30 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡